JPMorgan Chase & Co. (NYSE:JPM), along with Citigroup Inc. (NYSE:C) has its directors exploring new approaches to compensation, as a response to the amount of errors committed by management so far this year, say sources. As it happens, several top United States banks are looking over executive compensation amid soft financial-industry performance, stalling economic growth and widespread cost-cutting, according to the Wall Street Journal.
Don’t Miss: Are Investors Souring on Toyota?
Merck & Co. Inc. (NYSE:MRK) has reported new data for suvorexant, the investigational medicine the firm is developing for the treatment of insomnia. This 12-month evaluation was designed to assess the safety of suvorexant, while also studying its longer term efficacy. Specifically, results from the two-month discontinuation phase indicated that, following daily use of a consistent dose of suvorexant for one year, patients who stopped taking the medicine experienced a return of their sleeping difficulties to levels that were similar to those experienced by patients who took placebo over the course of the trial.
Microsoft Corporation (NASDAQ:MSFT) in the last week began supplying European consumers a “browser ballot screen” for Windows 8, which is a move that could be the first in a series of several steps the company will use to head off a new antitrust inquiry, says Reuters. In the meantime Microsoft has told European Union antitrust regulators that they “will comply immediately” with issues that officials in Brussels have raised about Internet Explorer, Windows 8 and its offshoot for tablets, Windows RT.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>